CROSSROADS STRATEGIES, LLC for GENENTECH, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, influenza, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and PDUFA Reauthorization. Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Budget/Appropriations BUD
Issues related to appropriations and federal health programs; reimbursement and vial size issues; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Taxation/Internal Revenue Code TAX
Implementation of Tax Cuts and Jobs Act (P.L.115-97). S.749, American Innovation and Jobs Act. Tax issues related to the Budget Reconciliation Process (H.R.5376).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Trademark legislative proposals. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.